The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. 1988

D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
Department of Anesthesia, University of California, San Francisco.

The duration of action and the pharmacokinetics of vecuronium were compared in patients with and without renal function. Twenty patients were studied: 12 with renal failure who were to receive kidney transplants from cadaveric donors, and eight with normal renal function. After oral premedication with diazepam, 10 mg, anesthesia was induced with thiopental, 4 mg/kg iv, and maintained with the inhalation of 60% nitrous oxide and 0.9-1.1% isoflurane, end-tidal concentration, in 40% oxygen. The force of thumb adduction in response to supramaximal ulnar nerve stimulation was monitored and recorded. An intravenous bolus of vecuronium, 0.1 mg/kg, was administered after 15 min of a stable end-tidal isoflurane concentration, as measured by mass spectrometry. Venous blood was then sampled at frequent intervals for 4 h following the bolus. Vecuronium concentrations in plasma were quantified by a sensitive and specific gas chromatographic assay. Data were analyzed by nonlinear least squares regression and described by a two-compartment model. The duration of neuromuscular blockade was longer in patients with renal failure than in those with normal renal function. This increased duration may be related to both a decreased plasma clearance and a prolonged elimination half-life of vecuronium in the renal failure group.

UI MeSH Term Description Entries
D007530 Isoflurane A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D009469 Neuromuscular Junction The synapse between a neuron and a muscle. Myoneural Junction,Nerve-Muscle Preparation,Junction, Myoneural,Junction, Neuromuscular,Junctions, Myoneural,Junctions, Neuromuscular,Myoneural Junctions,Nerve Muscle Preparation,Nerve-Muscle Preparations,Neuromuscular Junctions,Preparation, Nerve-Muscle,Preparations, Nerve-Muscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000769 Anesthesia, Inhalation Anesthesia caused by the breathing of anesthetic gases or vapors or by insufflating anesthetic gases or vapors into the respiratory tract. Insufflation Anesthesia,Anesthesia, Insufflation,Inhalation Anesthesia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014673 Vecuronium Bromide Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. NC-45,Norcuron,ORG-NC 45,ORG-NC-45,ORG-NC45,Vecuronium,Vecuronium Bromide, Quaternary Ion,Vecuronium Citrate,Vecuronium Hydrobromide,Vecuronium Hydrochloride,Vecuronium Maleate,Vecuronium Phosphate,Bromide, Vecuronium,Citrate, Vecuronium,Hydrobromide, Vecuronium,Hydrochloride, Vecuronium,Maleate, Vecuronium,NC 45,NC45,ORG NC 45,ORG NC45,ORGNC 45,ORGNC45,Phosphate, Vecuronium

Related Publications

D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
March 1986, Anesthesia and analgesia,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
December 1986, Anesthesia and analgesia,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
September 1985, Masui. The Japanese journal of anesthesiology,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
April 1990, Nihon juigaku zasshi. The Japanese journal of veterinary science,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
February 1991, Anesthesia and analgesia,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
May 1983, Anesthesiology,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
September 1986, British journal of anaesthesia,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
February 1993, Masui. The Japanese journal of anesthesiology,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
September 1992, Journal of cardiovascular pharmacology,
D P Lynam, and R Cronnelly, and K P Castagnoli, and P C Canfell, and J Caldwell, and J Arden, and R D Miller
August 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
Copied contents to your clipboard!